PubRank

M T Seymour

Author PubWeight™ 26.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002 2.00
2 Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001 1.74
3 DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002 1.68
4 A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002 1.61
5 The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006 1.56
6 Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003 1.52
7 Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed) 1985 1.49
8 A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991 1.42
9 Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 2000 0.99
10 Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer 2011 0.91
11 Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer 2012 0.90
12 Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 2002 0.89
13 Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer 2003 0.85
14 A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 2006 0.84
15 Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 1996 0.82
16 A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. Eur J Cancer 1997 0.79
17 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 2004 0.79
18 Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998 0.79
19 Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours. Eur J Cancer 1998 0.78
20 Intravenous irinotecan plus oral ciclosporin. Clin Oncol (R Coll Radiol) 2005 0.77
21 Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin Oncol (R Coll Radiol) 2010 0.76
22 Concomitant medications in cancer patients: should we be more active in their management? Ann Oncol 2009 0.75
23 What can the molecular pathologist offer for optimal decision making? Ann Oncol 2010 0.75
24 Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer 2001 0.75
25 Are we representing the true population in oncology trials? Ann Oncol 2009 0.75
26 Ambulatory chemotherapy. Clin Oncol (R Coll Radiol) 1992 0.75
27 Free fall from twelve storeys with survival. Br J Clin Pract 1987 0.75